(Q34976810)

5 August 2017

1 reference

title

The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review (English)

1 reference

5 August 2017

0 references

1 reference

1 reference

1 reference

Douglas L Riegert-Johnson

series ordinal

1

1 reference

5 August 2017

Gerald W Volcheck

series ordinal

2

1 reference

5 August 2017

publication date

1 October 2002

1 reference

Annals of Allergy, Asthma & Immunology

5 August 2017

published in

1 reference

5 August 2017

volume

89

1 reference

5 August 2017

issue

4

1 reference

5 August 2017

page(s)

400-406

1 reference

Henrik Dam--Discoverer of Vitamin K.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

Nutritional sources of vitamin K.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

Managing oral anticoagulant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

Epidemiology of anaphylaxis in Olmsted County: A population-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

Severe complication to phytomenadione after intramuscular injection in woman in labor. Case report and review of literature

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

The risks of death and of severe nonfatal reactions with high- vs low-osmolality contrast media: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

Intravenous Iron Dextran in Clinical Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

Bee-sting mortality in Australia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

Anaphylactoid and anaphylactic reactions. Hazards of beta-blockers.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

Increased Risk for Anaphylactoid Reaction from Contrast Media in Patients on β-Adrenergic Blockers or with Asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

Under-reporting of antibiotic anaphylaxis may put patients at risk

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

Vitamin K to reverse excessive anticoagulation: a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

A prospective randomized study to determine the optimal dose of intravenous vitamin K in reversal of over-warfarinization.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

Efficacy and safety of intravenous phytonadione (vitamin K1) in patients on long-term oral anticoagulant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

Case report of anaphylaxis from cisplatin/paclitaxel and a review of their hypersensitivity reaction profiles

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

Immune-mediated reactions to althesin (alphaxalone)

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

Anaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine: case report and review

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

Hypersensitivity reactions to teniposide (VM-26): an analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptide

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

Methods for preventing reactions secondary to Cremophor EL.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

Anaphylaxis caused by anti-cremophor EL IgG STS antibodies in a case of reaction to althesin.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

Histamine release in dogs by Cremophor El® and its derivatives: Oxethylated oleic acid is the most effective constituent

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

The hemodynamic effects of Cremophor-EL.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

Anaphylactic shock and vitamin K1

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

Severe complications of intravenous phytonadione therapy. Two cases, with one fatality

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

Vitamin K1 and anaphylactic shock

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

Acute cardiovascular collapse after intravenous phytonadione

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

Vitamin K-induced cardiovascular collapse

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962042-X

7 January 2021

10.1016/S1081-1206(10)62042-X

Identifiers

DOI

1 reference

release_ccg72hdoi5e43grlfywg7lmv5m

5 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ccg72hdoi5e43grlfywg7lmv5m

24 November 2022

mapped directly with Wikidata item

1 reference